BILLERICA, Mass. - Quanterix (NASDAQ:QTRX) Corporation (NASDAQ: QTRX), a company specializing in ultrasensitive biomarker detection, today announced a rescheduling of its fourth quarter and full year 2023 financial results release to coincide with the filing of its Annual Report on Form 10-K. The revised date for the investor call is now set for Thursday, February 29, 2024.
The decision to align the release of financial results with the annual report filing aims to provide investors with a comprehensive view of the company's performance. Quanterix anticipates that its revenue, gross margin, and cash usage for the year 2023 will meet the previously provided guidance on January 10, 2024.
A press release detailing the fourth quarter and full year financial results will precede the investor conference call and will be available on the Quanterix website. The call is scheduled for 4:30 p.m. ET on February 29, 2024, and interested parties can pre-register to obtain dial-in information.
The live webcast of the call will also be accessible through the Investors section of the Quanterix website, with an archived replay available for one year post-event.
Quanterix is known for its Simoa technology, which has set a high standard for early biomarker detection in various biological samples. This technology has supported extensive research across multiple disciplines, including neurology, oncology, immunology, cardiology, and infectious disease.
The company's precision instruments and digital immunoassay technology, coupled with its CLIA-certified Accelerator laboratory, have contributed to over 2,700 peer-reviewed publications.
The company's forward-looking statements regarding its financial performance are subject to the completion of standard quarter and year-end closing procedures and the audit of the financial statements for the year ended December 31, 2023. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially.
This article is based on a press release statement from Quanterix Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.